慢性非缺血性心功能衰竭合并血栓栓塞及药物治疗研究进展

doi:10.3969/j.issn.1004-583X.2024.01.014

摘要/Abstract

摘要：

慢性心功能衰竭是各种原因导致的心血管系统疾病的终末阶段,根据基础疾病的类型又可分为缺血性和非缺血性心功能衰竭(心衰)。血栓形成及栓塞是慢性心功能衰竭的严重并发症,包括卒中、外周动脉栓塞、深静脉血栓形成及肺栓塞等。目前指南推荐急性心功能衰竭、慢性心功能衰竭合并缺血性心血管疾病以及心房颤动(房颤)患者应用抗血小板、抗凝药物,而合并非缺血性疾病的慢性心衰患者,血栓形成和栓塞事件亦屡有报道,然而尚缺乏循证证据支持及明确临床抗栓治疗策略,因而严重影响着该类患者的病情进展及预后。本文就部分常见慢性非缺血性心衰合并血栓栓塞的现状和相关药物治疗的研究进展做一综述,旨在为该类疾病的临床防治提供参考。

中图分类号:

R541.6

马丽娜, 焦焕利, 曹振华. 慢性非缺血性心功能衰竭合并血栓栓塞及药物治疗研究进展[J]. 临床荟萃, 2024, 39(1): 75-79.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2024.01.014

https://huicui.hebmu.edu.cn/CN/Y2024/V39/I1/75

参考文献 52

[1]	McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur Heart J, 2021, 42(36):3599-3726. doi: 10.1093/eurheartj/ehab368 pmid: 34447992
[2]	Barkhudaryan A, Doehner W, Scherbakov N. Ischemic stroke and heart failure: Facts and numbers. An update[J]. J Clin Med, 2021, 10(5):1146. doi: 10.3390/jcm10051146 URL
[3]	Schäfer A, Flierl U, Bauersachs J. Anticoagulants for stroke prevention in heart failure with reduced ejection fraction[J]. Clin Res Cardiol, 2022, 111(1): 1-13. doi: 10.1007/s00392-021-01930-y
[4]	Adelborg K, Szépligeti S, Sundbøll J, et al. Risk of stroke in patients with heart failure: A population-based 30-year cohort study[J]. Stroke, 2017, 48(5):1161-1168. doi: 10.1161/STROKEAHA.116.016022 pmid: 28377383
[5]	Piazza G, Goldhaber SZ, Lessard DM, et al. Venous thromboembolism in heart failure: Preventable deaths during and after hospitalization[J]. Am J Med, 2011, 124(3):252-259. doi: 10.1016/j.amjmed.2010.10.014 pmid: 21396509
[6]	Fanola CL, Norby FL, Shah AM, et al. Incident heart failure and long-term risk for venous thromboembolism[J]. J Am Coll Cardiol, 2020, 75(2):148-158.
[7]	Mongirdiene A, Laukaitiene J, Skipskis V, et al. Platelet activity and its correlation with inflammation and cell count readings in chronic heart failure patients with reduced ejection fraction[J]. Medicina (Kaunas), 2021, 57(2):176.
[8]	Abdo AS, Kemp R, Barham J, et al. Dilated cardiomyopathy and role of antithrombotic therapy[J]. Am J Med Sci, 2010, 339(6):557-560. doi: 10.1097/MAJ.0b013e3181cf048a pmid: 20186041
[9]	Weintraub RG, Semsarian C, Macdonald P. Dilated cardiomyopathy[J]. Lancet, 2017, 390(10092):400-414. doi: S0140-6736(16)31713-5 pmid: 28190577
[10]	Jacobson AM, Darrah JR. Biventricular thrombi in substance-induced dilated cardiomyopathy[J]. CASE (Phila), 2020, 4(3):170-174. doi: 10.1016/j.case.2020.01.007 pmid: 32577600
[11]	翟玫, 黄丽燕, 王运红, 等. 扩张型心肌病合并心腔内血栓患者的临床特点分析[J]. 中国循环杂志, 2021, 36(6):563-566.
[12]	Lemaître AI, Picard F, Maurin V, et al. Clinical profile and midterm prognosis of left ventricular thrombus in heart failure[J]. ESC Heart Fail, 2021, 8(2): 1333-1341.
[13]	Zoni-Berisso M, Lercari F, Carazza T, et al. Epidemiology of atrial fibrillation: European perspective[J]. Clin Epidemiol, 2014, 6:213-220. doi: 10.2147/CLEP.S47385 pmid: 24966695
[14]	Ito K, Hongo K, Date T, et al. Tissue thrombin is associated with the pathogenesis of dilated cardiomyopathy[J]. Int J Cardiol, 2017, 228:821-827. doi: S0167-5273(16)33640-3 pmid: 27888761
[15]	Murugesan V, Pulimamidi VK, Rajappa M, et al. Elevated fibrinogen and lowered homocysteine-vitamin determinants and their association with left atrial thrombus in patients with rheumatic mitral stenosis[J]. Br J Biomed Sci, 2015, 72(3):102-106. doi: 10.1080/09674845.2015.11666804 URL
[16]	Topaloglu S, Aras D, Ergun K, et al. Plasma level of soluble P-selectin in patients with rheumatic mitral stenosis and sinus rhythm undergoing percutaneous mitral balloon valvuloplasty[J]. J Thromb Thrombolysis, 2007, 23(3):199-204. doi: 10.1007/s11239-006-9039-y URL
[17]	Aslanabadi N, Separham A, Valae Hiagh L, et al. Association of mean platelet volume with echocardiographic findings in patients with severe rheumatic mitral stenosis[J]. J Cardiovasc Thorac Res, 2019, 11(2):95-99. doi: 10.15171/jcvtr.2019.17 pmid: 31384402
[18]	Goyal A, Aggarwal P, Shrivastava A, et al. Effect of mitral regurgitation on systemic coagulation activity in rheumatic heart disease as assessed by D-dimer levels[J]. Cureus, 2021, 13(9):e17839.
[19]	GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: A systematic analysis for the Global Burden of Disease Study 2016[J]. Lancet, 2017, 390(10100):1151-1210. doi: S0140-6736(17)32152-9 pmid: 28919116
[20]	Pang H, Wang L, Liu J, et al. The prevalence and risk factors of venous thromboembolism in hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease[J]. Clin Respir J, 2018, 12(11):2573-2580. doi: 10.1111/crj.12959 pmid: 30207643
[21]	王辰, 杜敏捷, 曹大德. 慢性肺原性心脏病急性发作期肺细小动脉血栓形成的病理观察[J]. 中华医学杂志, 1997, 77(2): 123-125.
[22]	凌刘, 付娟娟. 肝素抗凝治疗对COPD合并肺心病患者凝血及肺动脉压影响的相关性分析[J]. 中华肺部疾病杂志, 2018, 11(4):435-439.
[23]	Yu H, Liu L, Wang J. The relationship between P-selectin on platelet membrane and platelet function in chronic cor pulmonale[J]. Zhonghua Nei Ke Za Zhi, 1995, 34(1):13-15.
[24]	Zheng YG, Yang T, Xiong CM, et al. Platelet distribution width and mean platelet volume in idiopathic pulmonary arterial hypertension[J]. Heart Lung Circ, 2015, 24(6):566-572. doi: 10.1016/j.hlc.2014.11.025 pmid: 25573235
[25]	Uçar H, Gür M, Gözükara MY, et al. Relationship between mean platelet volume and morning blood pressure surge in newly diagnosed hypertensive patients[J]. Anatol J Cardiol, 2015, 15(2):107-112. doi: 10.5152/akd.2014.5196 pmid: 25252294
[26]	Jiang X, Liu X, Liu X, et al. Low-dose aspirin treatment attenuates male rat salt-sensitive hypertension via platelet cyclooxygenase 1 and complement cascade pathway[J]. J Am Heart Assoc, 2020, 9(1):e013470. doi: 10.1161/JAHA.119.013470 URL
[27]	李泽浦, 唐丽萍, 徐兵, 等. 伴高同型半胱氨酸血症的高血压患者血栓前状态的特点及其对远期血栓事件的影响[J]. 中华心血管病杂志, 2015, 4(4):297-303.
[28]	Fujita S, Takeda Y, Kizawa S, et al. Platelet volume indices are associated with systolic and diastolic cardiac dysfunction, and left ventricular hypertrophy[J]. BMC Cardiovasc Disord, 2015, 15:52. doi: 10.1186/s12872-015-0047-8 URL
[29]	Li T, Jin J, Meng Z, et al. The different associations between platelet distribution width and hypertension subtypes in males and females[J]. Biosci Rep, 2020, 40(11):BSR20201747.
[30]	Abdul-Rahim AH, Perez AC, Fulton RL, et al. Risk of stroke in chronic heart failure patients without atrial fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca-Heart Failure (GISSI-HF) Trials[J]. Circulation, 2015, 131(17):1486-1494. doi: 10.1161/CIRCULATIONAHA.114.013760 pmid: 25810334
[31]	Freudenberger RS, Hellkamp AS, Halperin JL, et al. Risk of thromboembolism in heart failure: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)[J]. Circulation, 2007, 115(20):2637-2641. doi: 10.1161/CIRCULATIONAHA.106.661397 pmid: 17485579
[32]	Hjalmarsson C, Fu M, Zverkova Sandström T, et al. Risk of stroke in patients with heart failure and sinus rhythm: data from the Swedish Heart Failure Registry[J]. ESC Heart Fail, 2021, 8(1):85-94. doi: 10.1002/ehf2.13091 pmid: 33169527
[33]	Lip GY, Ponikowski P, Andreotti F, et al. Thrombo-embolism and antithrombotic therapy for heart failure in sinus rhythm. A joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis[J]. Eur J Heart Fail, 2012, 14(7):681-695. doi: 10.1093/eurjhf/hfs073 pmid: 22611046
[34]	Tang L, Wu YY, Lip GY, et al. Heart failure and risk of venous thromboembolism: A systematic review and meta-analysis[J]. Lancet Haematol, 2016, 3(1):e30-e44.
[35]	宋倩倩. 重症心力衰竭患者并发房颤的相关因素[J]. 现代诊断与治疗, 2021, 32(22), 3594-3596.
[36]	Pana TA, McLernon DJ, Mamas MA, et al. Individual and combined impact of heart failure and atrial fibrillation on ischemic stroke outcomes[J]. Stroke, 2019, 50(7):1838-1845. doi: 10.1161/STROKEAHA.119.025481 pmid: 31154943
[37]	Lip GY, Laroche C, Popescu MI, et al. Heart failure in patients with atrial fibrillation in Europe: A report from the EURObservational Research Programme Pilot survey on atrial fibrillation[J]. Eur J Heart Fail, 2015, 17(6):570-582. doi: 10.1002/ejhf.254 pmid: 25727992
[38]	Mehra MR, Vaduganathan M, Fu M, et al. A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: The COMMANDER HF trial[J]. Eur Heart J, 2019, 40(44):3593-3602. doi: 10.1093/eurheartj/ehz427 pmid: 31461239
[39]	Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease[J]. N Engl J Med, 2017, 377(14):1319-1330. doi: 10.1056/NEJMoa1709118 URL
[40]	Zannad F, Anker SD, Byra WM, et al. Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease[J]. N Engl J Med, 2018, 379(14):1332-1342. doi: 10.1056/NEJMoa1808848 URL
[41]	Melgaard L, Overvad TF, Jensen M, et al. Thromboembolic risk in nonanticoagulated patients with atrial fibrillation and valvular heart disease[J]. JACC Clin Electrophysiol, 2020, 6(13):1672-1682. doi: 10.1016/j.jacep.2020.07.005 pmid: 33334446
[42]	Chung I, Choudhury A, Patel J, et al. Soluble, platelet-bound, and total P-selectin as indices of platelet activation in congestive heart failure[J]. Ann Med, 2009, 41(1):45-51. doi: 10.1080/07853890802227089 pmid: 18618353
[43]	Gibbs CR, Blann AD, Watson RD, et al. Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm: Effects of angiotensin-converting enzyme inhibitor and beta-blocker therapy[J]. Circulation, 2001, 103(13):1746-1751. pmid: 11282905
[44]	白金祥, 韦建侠. 不同药物治疗老年高血压患者血栓前状态的对比分析[J]. 血栓与止血学, 2020, 26(6): 984-985.
[45]	McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure[J]. N Engl J Med, 2014, 371(11):993-1004. doi: 10.1056/NEJMoa1409077 URL
[46]	de Peuter OR, Souverein PC, Klungel OH, et al. Non-selective vs. selective beta-blocker treatment and the risk of thrombo-embolic events in patients with heart failure[J]. Eur J Heart Fail, 2011, 13(2):220-226. doi: 10.1093/eurjhf/hfq176 pmid: 20947572
[47]	Schäfer A, Fraccarollo D, Hildemann S, et al. Inhibition of platelet activation in congestive heart failure by aldosterone receptor antagonism and ACE inhibition[J]. Thromb Haemost, 2003 ;89(6):1024-1030.
[48]	Gromotowicz-Poplawska A, Kloza M, Aleksiejczuk M, et al. Nitric oxide as a modulator in platelet- and endothelium-dependent antithrombotic effect of eplerenone in diabetic rats[J]. J Physiol Pharmacol, 2019, 70(2). Epub 2019 Jul 22.
[49]	Kim H, Lee K, Choi HA, et al. Elevated blood urea nitrogen/creatinine ratio is associated with venous thromboembolism in patients with acute ischemic stroke[J]. J Korean Neurosurg Soc, 2017, 60(6):620-626. doi: 10.3340/jkns.2016.1010.009 URL
[50]	Elias S, Hoffman R, Saharov G, et al. Dehydration as a possible cause of monthly variation in the incidence of venous thromboembolism[J]. Clin Appl Thromb Hemost, 2016, 22(6):569-574. doi: 10.1177/1076029616649435 URL
[51]	Lowry E. Venous thromboembolism risk with glucocorticoid use[J]. Nurs Times, 2014, 110(6):23. pmid: 24669472
[52]	Stuijver DJF, Majoor CJ, van Zaane B, et al. Use of oral glucocorticoids and the risk of pulmonary embolism: A population-based case-control study[J]. Chest, 2013, 143(5):1337-1342. doi: S0012-3692(13)60332-3 pmid: 23258429

慢性非缺血性心功能衰竭合并血栓栓塞及药物治疗研究进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 52

相关文章 15

编辑推荐

Metrics

本文评价

[1]	刘蕾, 李明武, 万荣. 肺结核合并肺栓塞患者实验室指标的诊断价值[J]. 临床荟萃, 2024, 39(2): 134-139.
[2]	段芳, 崔炜. 血管扩张剂在急性心力衰竭救治中的应用原则[J]. 临床荟萃, 2023, 38(9): 773-778.
[3]	赵浩天, 李丽. 肺超声在心脏急重症疾病合并肺水肿中应用的研究进展[J]. 临床荟萃, 2023, 38(9): 832-837.
[4]	于晓东, 任晓艺, 刘美霞. 左西孟旦应用于机体重要器官疾病的研究进展[J]. 临床荟萃, 2023, 38(6): 573-576.
[5]	尚蒙, 王礼琳. 沙库巴曲/缬沙坦对慢性心力衰竭患者心律失常影响的研究进展[J]. 临床荟萃, 2023, 38(5): 459-464.
[6]	王震, 杨晓月, 李少杰, 王贤, 陈淑霞, 谷剑. 射血分数保留的心力衰竭合并心房颤动患者临床特征及再入院危险因素[J]. 临床荟萃, 2023, 38(4): 308-314.
[7]	冷婉铜, 陶洁. 多发性骨髓瘤患者治疗后发生静脉血栓栓塞的危险因素[J]. 临床荟萃, 2023, 38(4): 340-345.
[8]	王凤华, 魏茂提. 干式桑拿疗法治疗慢性心力衰竭的研究进展[J]. 临床荟萃, 2023, 38(4): 369-372.
[9]	张芳, 张伊超, 贾辛未, 李建龙, 陈春红. 心房颤动高CHA2DS2-VASc评分≥75岁住院患者随访1年结果分析[J]. 临床荟萃, 2023, 38(2): 117-120.
[10]	李娜娜, 江珊. 血清同型半胱氨酸、胱抑素C、超敏C-反应蛋白水平对急性ST段抬高型心肌梗死患者PCI术后并发心力衰竭的预测价值[J]. 临床荟萃, 2023, 38(2): 121-125.
[11]	董思语, 孙美, 田宇飞, 程虹, 何川. 脑动静脉畸形栓塞术后迟发性脑炎1例并文献复习[J]. 临床荟萃, 2023, 38(2): 170-174.
[12]	代菁, 陈华茜. 血液透析患者自发性肾破裂1例并文献复习[J]. 临床荟萃, 2023, 38(12): 1107-1111.
[13]	刘向东, 蔡延东, 秦延军, 李云松, 李亮, 高瑞姣, 任磊, 张彦荣. 运动性横纹肌溶解症并发急性肾功能不全及透析管相关性血栓1例并文献复习[J]. 临床荟萃, 2022, 37(9): 831-833.
[14]	邓媛媛, 岑梅, 金铭, 赵丽静, 张旖旎, 张智香. 慢性心力衰竭合并低蛋白血症患者营养管理的研究进展[J]. 临床荟萃, 2022, 37(9): 838-841.
[15]	王宁, 李勇. 簇集蛋白在心血管疾病中的研究进展[J]. 临床荟萃, 2022, 37(9): 842-845.